Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 425

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 8
Chunk 425
---
 included in research and development expenses. We expect to increase our administrative headcount as we prepare for commercialization of Tividenofusp alfa (DNL310, ETV:IDS) and advance our other product candidates through clinical development, which will increase our general and administrative expenses.

Gain from divestiture of small molecule programs

The gain from the divestiture of small molecule programs consists entirely of the non-cash gain associated with the divestiture of assets associated with select preclinical small molecule programs, including specified intellectual property, tangible assets and equipment used to conduct early-stage small molecule drug discovery from the Company, in exchange for equity consideration.

Interest and Other Income, Net 

Interest and other income, net, consists primarily of interest income, investment income earned on our cash, cash equivalents, and marketable securities, and sublease income, as well as an offset for interest expense on our finance lease liability.

28

Results of Operations

Comparison of the three and six months ended June 30, 2025 and 2024 

The following table sets forth the significant components of our results of operations (in thousands):

Three Months Ended June 30,Change20252024$%Operating expenses:Research and development$102,696 $91,399 $11,297 12 %General and administrative32,267 25,194 7,073 28 Total operating expenses134,963 116,593 18,370 16 Loss from operations(134,963)(116,593)(18,370)16 Interest and other income, net10,844 17,567 (6,723)(38)Net loss$(124,119)$(99,026)$(25,093)25 %

Six Months Ended June 30, 2025Change20252024$%Operating expenses:Research and development$218,923 $198,415 $20,508 10 %General and administrative61,620 50,430 11,190 22 Total operating expenses280,543 248,845 31,698 13 Gain from divestiture of small molecule programs— 14,537 (14,537)*Loss from operations(280,543)(234,308)(46,235)20 Interest and other income, net23,454 33,480 (10,026)(30)Net loss$(257,089)$(200,828)$(56,261)28 %